- Home
- VKTX vs RYTM Comparison
VKTX vs RYTM Comparison
Compare VKTX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VKTX | RYTM |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 6.4B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VKTX | RYTM |
|---|---|---|
| Price | $37.01 | $113.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $87.07 | ★ $125.77 |
| AVG Volume (30 Days) | ★ 2.9M | 833.9K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | N/A | $57.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $18.92 | $45.91 |
| 52 Week High | $49.67 | $122.20 |
Technical Indicators
Market Signals| Indicator | VKTX | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 59.90 |
| Support Level | $36.49 | $99.96 |
| Resistance Level | $39.99 | $122.20 |
| Average True Range (ATR) | 1.88 | 5.28 |
| MACD | 0.01 | 1.05 |
| Stochastic Oscillator | 57.05 | 61.92 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.